The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment.
about
Potential role of nuclear receptor ligand all-trans retinoic acids in the treatment of fungal keratitisHampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancerImproving cancer immunotherapy by targeting the STATe of MDSCsDynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in miceReciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential.The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.All-trans retinoic acid in combination with primaquine clears pneumocystis infectionMyeloid-derived suppressor cells in inflammatory bowel disease.Multicystic dedifferentiated retroperitoneal liposarcoma: tumour cyst fluid analysis and implications for managementRetinoic acid suppresses growth of lesions, inhibits peritoneal cytokine secretion, and promotes macrophage differentiation in an immunocompetent mouse model of endometriosis.Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells.Potential therapeutic anti-tumor effect of a Salmonella-based vaccine.Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.Overcoming tumor-mediated immunosuppression.Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets.Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment.A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies.Immunotherapeutic strategies targeting natural killer T cell responses in cancer.Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer.Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.Fungistatic activity of all-trans retinoic acid against Aspergillus fumigatus and Candida albicans.Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection.Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems.Myeloid-Derived Suppressor Cells Inhibit T Follicular Helper Cell Immune Response in Japanese Encephalitis Virus Infection.Increased frequency of myeloid-derived suppressor cells during active tuberculosis and after recent mycobacterium tuberculosis infection suppresses T-cell function.Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous MelanomaMDSCs are induced after experimental blunt chest trauma and subsequently alter antigen-specific T cell responses.
P2860
Q26796709-BCA298F9-898C-47EC-90D3-753E0AE8A222Q26863418-30736DA2-CAE6-4C5F-9E81-85F7141D9B15Q28066797-5BBF9314-5DED-4ED4-B0AE-E250F5781EF4Q33573652-39571B81-AB8C-4D00-9331-2DC6C6F4EF5CQ33720359-68B51E56-CBFB-4AFB-B0EA-EE38B4BC8DCBQ34315871-94F8AC7C-2A8D-444E-8F9A-83CC51BEA129Q34502899-9C41FBEB-52E7-420C-B732-AB8DB20AA5D6Q34545112-BDA5971B-BD1D-4AE2-815F-578C7FA280AFQ35554166-3BC5B7D8-4855-46AF-9B20-834C72E612CAQ35844190-328A517B-E8F3-4E5C-A7B7-721E92EF9CBAQ36007557-3D22767A-1DB8-4998-ADC3-2992AAAF5766Q36833481-A9725A3B-308C-4D62-BBA8-3102150FA549Q36869774-FA9F7A7D-0C51-493D-95CF-B36FEB8EDFA8Q37066106-D274470A-C6A6-4524-A3BD-E1C18ABF6EF2Q37170767-DB0C7C55-5FDA-46E7-83B3-3EDD1B65BF11Q37530067-4E8DD016-F5F8-4460-AB9D-3079193CEA6EQ38258842-F5192107-455C-43F8-B294-5FF58AED0E4EQ38262255-3AE03EAA-2156-4EA7-AEE2-3DB7159516FDQ38269370-2E8E00A0-0843-4A65-BB4E-60FB24EE6867Q38398117-F62F5B91-63DE-4BF0-80C2-6D7C921BD588Q38634685-6CACEB14-4639-4416-B496-1616246F18C0Q38890717-63BAFF95-9BED-4F7F-98BA-0FA5BE656FE6Q38939956-8CA4627E-5424-4505-87D6-66E7C1E2AE68Q39146128-A4996B15-9C30-4D72-8F3B-12F049448FF0Q40666647-DC45FC42-5E6D-487E-81E5-45C7200B76C0Q40976617-C0465068-7C55-42A9-AD6C-04CEADB3F8DBQ41787420-DDF0AFDA-5C74-4E1D-B3AE-63720CAD531CQ41924234-5B13A10F-8DA2-4B95-BE90-4C9BAD8C2FE9Q42253789-56D7E845-CE54-4489-A514-B999CAF5AC60Q42362520-E1562C39-528A-4FA8-BE1C-52428F51A669Q42373924-13C07BD3-E492-44E0-8CF4-3379608ADD47
P2860
The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
The restoration of myeloid-der ...... trans-retinoic acid treatment.
@en
The restoration of myeloid-der ...... trans-retinoic acid treatment.
@nl
type
label
The restoration of myeloid-der ...... trans-retinoic acid treatment.
@en
The restoration of myeloid-der ...... trans-retinoic acid treatment.
@nl
prefLabel
The restoration of myeloid-der ...... trans-retinoic acid treatment.
@en
The restoration of myeloid-der ...... trans-retinoic acid treatment.
@nl
P2093
P2860
P356
P1476
The restoration of myeloid-der ...... trans-retinoic acid treatment.
@en
P2093
Chang-Yuil Kang
Hyun-Jeong Ko
Jeong-Hwan Seo
Jung-Mi Lee
Yeon-Jeong Kim
Yun-Sun Kim
P2860
P304
P356
10.1002/IJC.26411
P577
2011-10-20T00:00:00Z